bemcentinib: Clinical Trials

10 trials of bemcentinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated. 10 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Terminated 4
Phase 15Terminated 3, Completed 2

Follow bemcentinib: new trials by email Literature Review of bemcentinib trials Research Report on bemcentinib

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
bemcentinib, pacritinib - Advanced Lung Adenocarcinoma
Phase 1 / Phase 2TerminatedThe University of Texas Health Science Center at San Antonio42024-12-272026-05-26
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
Bemcentinib, Pembrolizumab, Pemetrexed - Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2TerminatedBerGenBio ASA262023-03-032025-10-29
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
Bemcentinib, SoC - COVID-19
Phase 2CompletedBerGenBio ASA1152020-10-202024-10-16
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Rucaparib, Abemaciclib, pembrolizumab & bemcentinib - Mesothelioma, Malignant
Phase 2CompletedUniversity of Leicester1862019-01-282026-08-17
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Bemcentinib, Nab-paclitaxel, Gemcitabine - Cancer of Pancreas
Phase 1 / Phase 2TerminatedUniversity of Texas Southwestern Medical Center92019-01-032023-11-09
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
Bemcentinib - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Phase 2CompletedGWT-TUD GmbH452018-12-202021-12-21
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Pembrolizumab, Bemcentinib - Lung Cancer Metastatic, NSCLC Stage IV
Phase 2CompletedBerGenBio ASA992017-10-022025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Bemcentinib; pembrolizumab - Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Phase 2TerminatedBerGenBio ASA292017-07-262021-11-09
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Erlotinib, Bemcentinib - Non-Small Cell Lung Cancer
Phase 1 / Phase 2CompletedBerGenBio ASA402015-04-192025-02-26
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Bemcentinib, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2CompletedBerGenBio ASA1222014-10-222024-12-19

Conditions studied

Carcinoma, Non-Small-Cell Lung (3)  ·  Leukemia, Myeloid, Acute (2)  ·  Adenocarcinoma of Lung (1)  ·  COVID-19 (1)  ·  Inflammatory Breast Neoplasms (1)  ·  Mesothelioma, Malignant (1)  ·  Myelodysplastic Syndromes (1)  ·  Pancreatic Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

BerGenBio ASA (6)  ·  GWT-TUD GmbH (1)  ·  The University of Texas Health Science Center at San Antonio (1)  ·  University of Leicester (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (7)  ·  Norway (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Greece (1)  ·  Hungary (1)  ·  India (1)  ·  Netherlands (1)  ·  Poland (1)  ·  South Africa (1)

Top investigators

Dean Fennell, PhD, FRCP (1)  ·  Dr. Lauren Byers, MD (1)  ·  Hani Gabra (1)  ·  Sonja Loges, MD (1)  ·  Syed Kazmi, MD (1)  ·  Uwe Platzbecker, Prof. (1)

Results publications

PMID 33515503, PMID 35157829, PMID 35492873, PMID 40122885

NIH funding

2016 (2), R01CA269766 (1)